Wall Street Zen Upgrades Eton Pharmaceuticals to 'Buy'

Analysts cite potential in company's pipeline of rare disease treatments

Mar. 22, 2026 at 8:08am

Got story updates? Submit your updates here. ›

Wall Street Zen has upgraded shares of Eton Pharmaceuticals (NASDAQ:ETON) from a hold rating to a buy rating, citing the company's promising pipeline of specialty pharmaceutical products for rare and underserved diseases. The upgrade comes after several other research firms also issued positive reports on Eton, lifting their price targets and ratings on the stock.

Why it matters

Eton Pharmaceuticals is a relatively young specialty pharmaceutical company that has been working to build a diversified portfolio of both generic and branded treatments, with a focus on areas with limited competition. The Wall Street Zen upgrade and other positive analyst sentiment suggest growing confidence in Eton's ability to successfully bring new products to market and grow its business.

The details

In its upgrade report, Wall Street Zen highlighted Eton's expertise in developing complex molecules and hormone therapies, which the firm believes positions the company well to address treatment areas with high patient need. Other analysts, including those from Craig Hallum and B. Riley Financial, have also recently lifted their price targets and ratings on Eton, citing the company's progress in advancing its product pipeline.

  • On March 19, 2026, Eton Pharmaceuticals reported its latest quarterly earnings results.
  • On March 22, 2026, Wall Street Zen published its upgrade report on Eton Pharmaceuticals.

The players

Eton Pharmaceuticals

A specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases.

Wall Street Zen

A research firm that covers the pharmaceutical industry and has upgraded Eton Pharmaceuticals to a 'buy' rating.

Craig Hallum

A research firm that has lifted its price target and rating on Eton Pharmaceuticals.

B. Riley Financial

A research firm that has lifted its price target and rating on Eton Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

Eton Pharmaceuticals' focus on rare and underserved disease treatments, coupled with the company's expertise in complex molecules and hormone therapies, appears to be resonating with Wall Street analysts. The positive sentiment around Eton's pipeline and growth prospects suggests the company may be well-positioned to continue expanding its business in the specialty pharmaceutical market.